Pharmacist FAQ

Click on each question to see the responses

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

P-MAPP participation brings the ultimate end-user of the healthcare system, the patient, into the process of evaluating the reasons for medication non-adherence and persistence as observed in the “real world.”

Patients have the opportunity via the IMB surveys to define the specific drivers of their non-adherence behaviours and will benefit from their interactions with the pharmacists regarding the application of personalized strategies to improve adherence.

Most important, patients will benefit from improved medication adherence by reducing emergency room visits, hospitalisations and other morbid events triggered by non adherence.

For pharmacists, the P-MAPP:

➔ Tracks patterns and reasons for poor adherence and makes the data available to the patient’s healthcare team, including the pharmacist, thereby shortening the time between problem identification and resolution.

➔ Positions the pharmacist as the key facilitator among the patient, the prescriber and the payer in personalizing strategies to improve medication adherence.

➔ Increased medication adherence leads to increases in refill rates at the pharmacy.

➔ The P-MAPP encourages pharmacists to come out from “behind the counter” and engage with patients directly.

➔ Training provided by the P-MAPP sharpens pharmacists’ skill sets in Motivational Interviewing.

➔ The data collected in the P-MAPP will be able to attribute improvements in medication adherence directly with pharmacists’ performance and potentially strengthen the value of Provider Status.
First confirm that the patient is taking one of the target medications, and review any data related to the patient’s refill history. Your goal is to identify those patients who are likely “non-adherers”. Then have the patient complete the ARMS-12© risk assessment. If the patient qualifies based on the ARMS-12© score, then begin the enrollment process as described in the P-MAPP Playbook.
Fill/refill information on all medications dispensed by your pharmacy will be sent to P-MAPP on a scheduled basis.
Verification of a signed HIPAA form is required as part of the patient enrollment process. This form should be kept with the patient’s pharmacy records.
Pharmacists are asked to help enroll patients, and to verify participants’ HIPAA, Informed Consent and Authorization for Release of Health Information. Then, it is the participants’ responsibility to complete their surveys. Importantly, it is the pharmacists’ responsibility to schedule and conduct Motivational Interviews for those patients randomized to the IMB Group. P-MAPP will provide e-mail and phone reminders, but certainly additional reminders from pharmacy staff are very helpful. Your encouragement is appreciated.
All patient-related healthcare information submitted is automatically de-identified upon upload into the P-MAPP database, where it is aggregated with the data from thousands of other P-MAPP participants. All data are encrypted and stored on protected servers.
Patients’ survey responses and other related health information including medical records, pharmacy and claims data, as well as data extracted from devices (e.g. glucose monitors) will be integrated and standardized to produce an actionable database. Using artifical intelligence (AI) the data will be analyzed related to all primary and secondary outcomes defined in the protocol.
Health records, pharmacy and medical claims records will provide additional data to support and validate the voice-of-the-patient information submitted via Patient Reported Outcome surveys. Targeted health information that will be “pulled” into the P-MAPP database includes data related to hospitalizations, emergency room visits, office visits, medication side effects, and clinical laboratory tests.
Yes. The patients’ status and progress reports are available via the Pharmacy Dashboard accessible upon log-in.
There is no direct payment to patients for their participation in this program.